Who are Active compared Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, Healive+Healive, CPA, 23vPPV+TIV, Td.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/active-compared-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Active compared Vaccine — Competitive Intelligence Brief

Active compared Vaccine (Active compared Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

phase 3 vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Active compared Vaccine (Active compared Vaccine) — Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. This is a recombinant protein vaccine designed to stimulate immune responses against a specific pathogen or disease target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active compared Vaccine TARGET	Active compared Vaccine	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	phase 3	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Healive+Healive	Healive+Healive	Sinovac Biotech Co., Ltd	marketed	Combination vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
CPA	CPA	ImmunoVaccine Technologies, Inc. (IMV Inc.)	marketed	Therapeutic cancer vaccine
23vPPV+TIV	23vPPV+TIV	Jiangsu Province Centers for Disease Control and Prevention	marketed	Combination vaccine
Td	Td	University of Florida	marketed	Toxoid vaccine	Tetanus toxin (tetanospasmin) and diphtheria toxin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Active compared Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/active-compared-vaccine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab